New drug shows promise for heart muscle disease symptoms

NCT ID NCT02590809

Completed Symptom relief Sponsor: University Hospital, Bordeaux Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial tested a drug called BX1514M in 38 people with hypertrophic cardiomyopathy, a genetic heart condition that can cause shortness of breath, chest pain, and dizziness. The drug aims to improve blood flow by tightening veins, which may reduce blockages in the heart. Participants took the drug or a placebo for 30 days, and researchers measured how far they could walk in six minutes.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: BX1514M
What this could lead to: If it works, this could point toward a new treatment option for hypertrophic cardiomyopathy symptoms like shortness of breath and chest pain.
What could go wrong: This is a small, early-phase trial with only 38 people. The drug may not work better than placebo, and results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HYPERTROPHIC CARDIOMYOPATHY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hypertrophic cardiomyopathy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HYPERTROPHIC CARDIOMYOPATHY

Contacts and locations

Locations

CHU de Bordeaux

Bordeaux, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.